INMB - Spark Newswire

3 minute read

INmune Bio, Inc. Announces Pre-Clinical Data That Support A Pioneering Approach To Treating Duchenne Muscular Dystrophy

January 25, 8:45 AM

INmune Bio, Inc.(NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, in collaboration with

INMB

3 minute read

INmune Bio Data At ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence Of Cancer Killing Memory Like NK Cells In Patients With AML/MDS Following Treatment With INKmune

By Benzinga Newsdesk

December 8, 9:10 AM

INmune Bio, Inc. (NASDAQ:INMB) ("INMB" or "the Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system

INMB

3 minute read

INmune Bio Reports Combination Therapy With INB03™ Overcomes Resistance To Trastuzumab-Deruxtecan In MUC4 Expressing HER2+ Breast Cancer

By Benzinga Newsdesk

December 6, 5:01 PM

Neutralizing soluble TNF with INB03™ overcomes resistance to trastuzumab-deruxtecan in MUC4 expressing HER2+breast cancer. Combination therapy of INB03™ and trastuzumab-deruxtecan presented at the 45th

INMB

1 minute read

Earnings

Recap: INmune Bio Q2 Earnings

By Benzinga Insights

August 3, 6:51 PM

INmune Bio (NASDAQ:INMB) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings INmune Bio beat estimated earnings by 24.0%, reporting an EPS of $-0.38 versus an estimate of $-0.5.

INMB

2 minute read

12 Health Care Stocks Moving In Tuesday’s Intraday Session

By Benzinga Insights

May 24, 2:36 PM

BIMI

1 minute read

BTIG Maintains Buy on INmune Bio, Lowers Price Target to $14

By Benzinga Newsdesk

May 24, 9:31 AM

BTIG analyst Thomas Shrader maintains INmune Bio (NASDAQ:INMB) with a Buy and lowers the price target from $31 to $14.

INMB

3 minute read

The Daily Biotech Pulse: INmune Bio’s Planned Alzheimer’s Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures

By Vandana Singh

May 24, 8:24 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ABBV

1 minute read

INmune Bio, Inc. To Provide Additional Manufacturing Information To FDA As Part Of IND Application For XPro1595 In Alzheimer’s Disease

By Benzinga Newsdesk

May 23, 4:00 PM

INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced

INMB

30 minute read

Earnings Scheduled For May 5, 2022

By Benzinga Insights

May 5, 4:43 AM

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

AAOI

4 minute read

60 Biggest Movers From Yesterday

By Lisa Levin

April 26, 4:58 AM

Gainers

AGE

Feed Symbols: INMB